Deutsche Bank Initiates Coverage On Kymera Therapeutics with Hold Rating, Announces Price Target of $120
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsInitiationPrice Target
Deutsche Bank analyst David Hoang initiates coverage on Kymera Therapeutics (NASDAQ:KYMR) with a Hold rating and announces Price Target of $120.
Deutsche Bank analyst David Hoang initiates coverage on Kymera Therapeutics (NASDAQ:KYMR) with a Hold rating and announces Price Target of $120.